Maria Suarez Lopez, MD
Endocrinology, Diabetes & Metabolism · Virginia Beach, VANPI 1154730869
Payments from drug & device makers
Across 123 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$396
- Corcept Therapeutics$234
- Radius Health, Inc.$222
- Astellas Pharma US Inc$207
- Medtronic$204
- plus $2K from 23 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50
What the payments were for
- Travel & lodging$75020%
- Food & beverage$2,90976%
- Education$1704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 12 | $1,025 |
| Lilly USA, LLC | 22 | $396 |
| Corcept Therapeutics | 10 | $234 |
| Radius Health, Inc. | 9 | $222 |
| Astellas Pharma US Inc | 4 | $207 |
| Medtronic | 5 | $204 |
| Xeris Pharmaceuticals, Inc. | 9 | $194 |
| BETA Bionics, Inc. | 8 | $193 |
| Boehringer Ingelheim | 8 | $164 |
| Sequel Med Tech, LLC | 1 | $160 |
| Amgen(2 entities) | 7 | $149 |
| Insulet Corporation | 3 | $123 |
| Bayer | 7 | $119 |
| Mannkind Corporation | 1 | $77 |
| Dexcom, Inc. | 1 | $75 |
| Kyowa Kirin, Inc. | 2 | $50 |
| AbbVie | 2 | $27 |
| Endo USA, Inc. | 1 | $23 |
| AstraZeneca | 1 | $20 |
| Pfizer | 1 | $18 |
| Companion Medical, Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $18 |
| Ascendis Pharma Endocrinology Inc | 1 | $18 |
| Abbott | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iLet Bionic Pancreas$316
- TWIIST$160
How this compares
$3,829 in reported general payments places this provider in the 65th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $249,820 |
| JardianceEmpagliflozin | 231 | $194,201 |
| TrulicityDulaglutide | 49 | $66,939 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $52,725 |
| MounjaroTirzepatide | 39 | $42,073 |
| Tresiba Flextouch U-100Insulin Degludec | 75 | $41,946 |
| Tresiba Flextouch U-200Insulin Degludec | 32 | $32,457 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 21 | $23,919 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $18,989 |
| V-Go 20Sub-Q Insulin Device, 20 Unit | 19 | $17,823 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $17,541 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $14,319 |
| FarxigaDapagliflozin Propanediol | 12 | $12,595 |
| JanuviaSitagliptin Phosphate | 12 | $10,627 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $10,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,025 | $253,024242 claims |
| Boehringer IngelheimJardiance | $164 | $194,201231 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humalog Mix 75-25 | $396 | $117,856123 claims |
| AstraZenecaFarxiga | $20 | $12,59512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Virginia Beach
- Howard HarrisonVirginia Beach$47K
- Ana Marie DizonVirginia Beach$10K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.